- Home
- ITRG vs VNDA Comparison
ITRG vs VNDA Comparison
Compare ITRG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRG
- VNDA
- Stock Information
- Founded
- ITRG 1997
- VNDA 2002
- Country
- ITRG Canada
- VNDA United States
- Employees
- ITRG N/A
- VNDA N/A
- Industry
- ITRG Precious Metals
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- ITRG Basic Materials
- VNDA Health Care
- Exchange
- ITRG Nasdaq
- VNDA Nasdaq
- Market Cap
- ITRG 302.5M
- VNDA 249.4M
- IPO Year
- ITRG N/A
- VNDA 2006
- Fundamental
- Price
- ITRG $2.56
- VNDA $4.61
- Analyst Decision
- ITRG Strong Buy
- VNDA Strong Buy
- Analyst Count
- ITRG 2
- VNDA 2
- Target Price
- ITRG $3.25
- VNDA $16.50
- AVG Volume (30 Days)
- ITRG 2.0M
- VNDA 460.3K
- Earning Date
- ITRG 08-13-2025
- VNDA 11-05-2025
- Dividend Yield
- ITRG N/A
- VNDA N/A
- EPS Growth
- ITRG N/A
- VNDA N/A
- EPS
- ITRG 0.09
- VNDA N/A
- Revenue
- ITRG $148,447,000.00
- VNDA $203,467,000.00
- Revenue This Year
- ITRG $871.24
- VNDA $15.45
- Revenue Next Year
- ITRG N/A
- VNDA $37.82
- P/E Ratio
- ITRG $30.13
- VNDA N/A
- Revenue Growth
- ITRG N/A
- VNDA 11.78
- 52 Week Low
- ITRG $0.79
- VNDA $3.81
- 52 Week High
- ITRG $2.57
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- ITRG 83.18
- VNDA 51.38
- Support Level
- ITRG $2.34
- VNDA $4.54
- Resistance Level
- ITRG $2.55
- VNDA $4.92
- Average True Range (ATR)
- ITRG 0.12
- VNDA 0.19
- MACD
- ITRG 0.05
- VNDA 0.02
- Stochastic Oscillator
- ITRG 98.05
- VNDA 38.00
About ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.